{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:18:01Z","timestamp":1791292681769,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.revmed.2004.12.013","type":"journal-article","created":{"date-parts":[[2005,2,8]],"date-time":"2005-02-08T10:15:25Z","timestamp":1107857725000},"page":"485-500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Le rituximab : une bioth\u00e9rapie originale dans les maladies auto-immunes"],"prefix":"10.1016","volume":"26","author":[{"given":"J.","family":"Sibilia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sordet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2004.12.013_bib1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/art.10898","article-title":"Low prevalence of antibodies to glucose-6-phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders","volume":"48","author":"Matsumoto","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib2","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00002281-200305000-00011","article-title":"The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets","volume":"15","author":"Dorner","year":"2003","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.revmed.2004.12.013_bib3","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B Lymphocyte stimulator overexpression in patients with systemic lupus erythematous","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/ni829","article-title":"Dendritic cells CD40-independent immunoglobulin class switching through BlyS and APRIL","volume":"3","author":"Litinskiy","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.4049\/jimmunol.172.2.762","article-title":"Cutting Edge: BAFF Regulates CD21\/35 and CD23 Expression Independent of Its B Cell Survival Function","volume":"172","author":"Gorelik","year":"2004","journal-title":"J. Immunol"},{"key":"10.1016\/j.revmed.2004.12.013_bib6","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1002\/art.11299","article-title":"Generation and characterization of lymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator","volume":"48","author":"Baker","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1084\/jem.189.10.1639","article-title":"A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus","volume":"189","author":"Chan","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib8","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.4049\/jimmunol.172.8.4709","article-title":"B cell-dependent TCR diversification","volume":"172","author":"Joao","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib9","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.20021293","article-title":"Prevention of arthritis by interleukin 10-producing B cells","volume":"197","author":"Mauri","year":"2003","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib10","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment","volume":"2","author":"Bienvenu","year":"2001","journal-title":"Hematol. J."},{"key":"10.1016\/j.revmed.2004.12.013_bib11","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/416603a","article-title":"Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors","volume":"416","author":"Leadbetter","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.revmed.2004.12.013_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002371-200105000-00011","article-title":"Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies","volume":"24","author":"Treon","year":"2001","journal-title":"J. Immunother."},{"key":"10.1016\/j.revmed.2004.12.013_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1006\/clim.2000.4980","article-title":"Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)","volume":"98","author":"Gonzalez-Stawinski","year":"2001","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib14","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/blood-2003-03-1005","article-title":"No clinical evidence for CD4+ cell depletion caused by rituximab","volume":"102","author":"Saville","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib15","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s002510050412","article-title":"Mice carrying CD20 gene disruption","volume":"48","author":"O\u2019keefe","year":"1998","journal-title":"Immunogenetics"},{"key":"10.1016\/j.revmed.2004.12.013_bib16","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s002620050016","article-title":"Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells","volume":"48","author":"Shan","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.revmed.2004.12.013_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1006\/bcmd.2000.0287","article-title":"Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis","volume":"26","author":"Hofmeister","year":"2000","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.revmed.2004.12.013_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1182\/blood.V99.4.1314","article-title":"The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism","volume":"99","author":"Pedersen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib19","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib20","first-page":"534","article-title":"Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts\/microdomains of B lymphoma cells","volume":"63","author":"Semac","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.revmed.2004.12.013_bib21","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib22","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.4049\/jimmunol.172.5.3280","article-title":"Rituximab infusion promotes rapid complement depletion and acute CD 20 Loss in chronic lymphocytic leukemia","volume":"172","author":"Kennedy","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib23","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1073\/pnas.0437875100","article-title":"Variation in gene expression patterns in follicular lymphoma and the response to rituximab","volume":"100","author":"Bohen","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.revmed.2004.12.013_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S0093-7754(03)00261-6","article-title":"Mechanism of action and resistance to monoclonal antibody therapy","volume":"30","author":"Villamor","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib25","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood.V91.5.1644","article-title":"Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies","volume":"91","author":"Shan","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib26","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/sj.leu.2402226","article-title":"CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells","volume":"15","author":"Selenko","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.12.013_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1046\/j.1365-2567.2002.01495.x","article-title":"CD20-mediated apoptosis: signalling through lipid rafts","volume":"107","author":"Deans","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.revmed.2004.12.013_bib28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V99.3.1038","article-title":"The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction","volume":"99","author":"Byrd","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib29","first-page":"836","article-title":"Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma","author":"Alas","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.revmed.2004.12.013_bib30","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.2003.06.012","article-title":"Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance","volume":"21","author":"Bannerji","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00262-001-0247-1","article-title":"Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines","volume":"51","author":"Cardarelli","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.revmed.2004.12.013_bib32","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib33","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib34","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1046\/j.1365-2141.2001.03166.x","article-title":"Complement activation plays a key role in the side-effects of rituximab treatment","volume":"115","author":"Van Der Kolk","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib36","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-02-0469","article-title":"In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas","volume":"101","author":"Manches","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib37","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib40","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1200\/JCO.2003.05.013","article-title":"Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma","volume":"21","author":"Weng","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib41","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2003-07-2548","article-title":"Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia","volume":"103","author":"Farag","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib42","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib43","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1365-3083.2000.00745.x","article-title":"rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms","volume":"51","author":"Harjunpaa","year":"2000","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib44","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.171.3.1581","article-title":"Complement activation determines the therapeutic activity of rituximab in vivo","volume":"171","author":"Di Gaetano","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib45","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2002-03-0876","article-title":"An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab","volume":"101","author":"Kennedy","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib46","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.revmed.2004.12.013_bib47","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/sj.leu.2402424","article-title":"Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils","volume":"16","author":"Van der Kolk","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.revmed.2004.12.013_bib48","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3109\/10428190109099335","article-title":"Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma","volume":"42","author":"Harjunpaa","year":"2001","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.revmed.2004.12.013_bib49","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib50","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1034\/j.1600-0609.2003.00007.x","article-title":"Loss of CD20 expression in relapsed lymphomas after rituximab therapy","volume":"70","author":"Haidar","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib51","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1046\/j.1365-2141.2002.03843.x","article-title":"Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review","volume":"119","author":"Kennedy","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib52","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1046\/j.1365-2141.2001.03019.x","article-title":"Loss of CD 20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis","volume":"114","author":"Foran","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib53","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2002-06-1639","article-title":"Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance","volume":"101","author":"Manshouri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib54","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.4049\/jimmunol.169.6.2886","article-title":"Colocalization of the cell receptor and CD 20 followed by activation-dependent dissocation in distinct lipid rafts","volume":"15","author":"Petrie","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.revmed.2004.12.013_bib55","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1182\/blood-2003-02-0450","article-title":"Agranulocytosis unresponsive to growth factors following rituximab in vivo purging","volume":"101","author":"Rose","year":"2003","journal-title":"Blood"},{"issue":"Suppl 6","key":"10.1016\/j.revmed.2004.12.013_bib56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1053\/sonc.2002.32747","article-title":"Beyond immunochemotherapy: combinations of rituximab with cytokines interferon-alpha2a and granulocyte colony stimulating factor","volume":"29","author":"Kimby","year":"2002","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib57","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood-2003-10-3597","article-title":"Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients","volume":"103","author":"Berentsen","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib58","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.11181","article-title":"Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis","volume":"48","author":"Cambridge","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib59","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood-2003-12-4331","article-title":"Rituximab administration following autologous stem cell transplantion for multiple myeloma is associated with severe IgM deficiently","volume":"103","author":"Lim","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib60","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1","article-title":"Plasma cells for a lifetime?","volume":"32","author":"Manz","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"suppl 262","key":"10.1016\/j.revmed.2004.12.013_bib61","first-page":"594","article-title":"Effects of rituximab on B cells in Human SLE","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib62","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/1529-0131(200109)44:9<2029::AID-ART352>3.0.CO;2-2","article-title":"Presence of a population of CD20+, CD38- B lymphocytes with defective proliferation responsiveness in the synovial compartment of patients with rheumatoid arthritis","volume":"44","author":"Reparon-Schuijt","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib63","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/art.10947","article-title":"Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy","volume":"48","author":"Silverman","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib64","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/rheumatology\/38.11.1150","article-title":"Remission of inflammatory arthropathy in association with anti-CD20 therapy for non-Hodgkin's lymphoma","volume":"38","author":"Protheroe","year":"1999","journal-title":"Rheumatol."},{"key":"10.1016\/j.revmed.2004.12.013_bib65","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatol."},{"key":"10.1016\/j.revmed.2004.12.013_bib66","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/ard.61.10.883","article-title":"Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion","volume":"61","author":"Leandro","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2004.12.013_bib67","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/art.10467","article-title":"Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells","volume":"46","author":"De Vita","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib68","first-page":"3420","article-title":"Successful treatment of infliximab-refractory rheumatoid arthritis with rituximab","volume":"46","author":"Tuscano","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2004.12.013_bib69","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2004.12.013_bib70","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2004.12.013_bib71","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/ar759","article-title":"SLE - Rituximab in lupus","volume":"5","author":"Eisenberg","year":"2003","journal-title":"Arthritis Res. Ther."},{"issue":"Suppl 9","key":"10.1016\/j.revmed.2004.12.013_bib72","first-page":"387","article-title":"B lymphocyte depletion as a novel treatment for systemic lupus erythematous: phase I\/II trial of rituximab (Rituxan) in SLE","volume":"44","author":"Anolik","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib73","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus","volume":"46","author":"L\u00e9andro","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib74","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1191\/0961203303lu449cr","article-title":"Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy","volume":"12","author":"Weide","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2004.12.013_bib75","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1191\/0961203303lu453cr","article-title":"Remission of refractory lupus nephritis with a protocol including rituximab","volume":"12","author":"Fra","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.revmed.2004.12.013_bib76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2141.2002.03278.x","article-title":"Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus","volume":"116","author":"Perrotta","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib77","first-page":"381","article-title":"Rituximab in antiphospholipid syndrome","volume":"5","author":"Merrill","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.revmed.2004.12.013_bib78","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","article-title":"IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab","volume":"52","author":"Levine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.revmed.2004.12.013_bib79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.revmed.2004.12.013_bib80","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","article-title":"Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies","volume":"27","author":"Renaud","year":"2003","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.revmed.2004.12.013_bib81","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/ajh.10413","article-title":"Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)","volume":"74","author":"Narang","year":"2003","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib82","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib83","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1182\/blood-2002-02-0392","article-title":"Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura","volume":"99","author":"Stasi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib84","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1034\/j.1600-0609.2002.02686.x","article-title":"Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study","volume":"69","author":"Giagounidis","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajh.1081","article-title":"Refractory autoimmune thrombocytopenic purpura treatment with Rituximab","volume":"67","author":"Patel","year":"2001","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib86","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1046\/j.1365-2141.2002.03753.x","article-title":"Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome","volume":"118","author":"Heelan","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib87","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2004.12.013_bib88","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/08880010390232781","article-title":"Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab","volume":"20","author":"Gottardo","year":"2003","journal-title":"Pediatr. Hematol. Oncol."},{"key":"10.1016\/j.revmed.2004.12.013_bib89","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1182\/blood-2002-11-3547","article-title":"Rituximab for the treatment of refractory autoimmune hemolytic anemia in children","volume":"101","author":"Zecca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib90","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.4065\/78.11.1340","article-title":"Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome","volume":"78","author":"Shanafelt","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.revmed.2004.12.013_bib91","first-page":"336","article-title":"B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002; 87:189-95. Erratum in","volume":"87","author":"Zaja","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2004.12.013_bib92","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1182\/blood-2002-01-0018","article-title":"Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment","volume":"99","author":"Morselli","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib93","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood-2002-04-1213","article-title":"Severe cold hemagglutinin disease (CHD) successfully treated with rituximab","volume":"100","author":"Engelhardt","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1046\/j.1365-2141.2001.03078.x","article-title":"Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease","volume":"115","author":"Berentsen","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib95","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1046\/j.1365-2141.2002.03537_6.x","article-title":"Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results","volume":"117","author":"Pulik","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib96","first-page":"223","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders","volume":"88","author":"Trape","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.revmed.2004.12.013_bib97","first-page":"I38","article-title":"Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 2003; 138:105-8. Summary for patients in","volume":"138","author":"Zheng","year":"2003","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib98","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib99","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1046\/j.1365-2141.2002.03835_5.x","article-title":"Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (rituximab)","volume":"119","author":"Kain","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib100","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/art.11109","article-title":"American College of Rheumatology ad hoc Committee on Immunologic Testing Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma","volume":"49","author":"Somer","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/00003072-200202000-00019","article-title":"F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy","volume":"27","author":"Shih","year":"2002","journal-title":"Clin. Nucl. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib102","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1002\/1529-0131(200112)44:12<2836::AID-ART471>3.0.CO;2-W","article-title":"Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy","volume":"44","author":"Specks","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib103","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/ard.61.10.922","article-title":"Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)","volume":"61","author":"Arzoo","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2004.12.013_bib104","first-page":"2090","article-title":"Rituximab for idiopathic membranous nephropathy. Lancet 2002; 360:923-4. Erratum in","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2004.12.013_bib105","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy: a one-year prospective study","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.revmed.2004.12.013_bib106","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2230.2003.01283.x","article-title":"Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)","volume":"28","author":"Cooper","year":"2003","journal-title":"Clin. Exp. Dermatol."},{"key":"10.1016\/j.revmed.2004.12.013_bib107","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD 20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.revmed.2004.12.013_bib108","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.revmed.2004.12.013_bib109","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1182\/blood-2002-09-2856","article-title":"Efficacy and safety of rituximab in type II mixed cryoglobulinemia","volume":"101","author":"Zaja","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib110","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib111","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1136\/ard.2002.004929","article-title":"Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis","volume":"62","author":"Lamprecht","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2004.12.013_bib112","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1067\/S0022-3476(03)00382-2","article-title":"Rituximab therapy for multisystem autoimmune diseases in pediatric patients","volume":"143","author":"Binstadt","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.revmed.2004.12.013_bib113","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness","volume":"100","author":"Van der Kolk","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib114","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1182\/blood.V96.3.1184.015k54_1184_1186","article-title":"Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab","volume":"96","author":"Sharma","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib115","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJM200101043440120","article-title":"Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab","volume":"344","author":"Dervite","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib116","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib117","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab","volume":"348","author":"Voog","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2004.12.013_bib118","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/1042819021000055110","article-title":"Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder","volume":"44","author":"Jourdan","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.revmed.2004.12.013_bib119","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood.V100.5.1765.h81702001765_1765_1773","article-title":"Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects","volume":"100","author":"Rose","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib120","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1182\/blood-2003-05-1532","article-title":"Rituximab-associated immune myelopathy","volume":"102","author":"Papadaki","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib121","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0145-2126(01)00183-7","article-title":"Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases","volume":"26","author":"Papadaki","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.revmed.2004.12.013_bib122","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1056\/NEJM200306263482619","article-title":"Interstitial pneumonitis related to rituximab therapy","volume":"348","author":"Burton","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2004.12.013_bib123","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00277-003-0747-5","article-title":"Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab","volume":"83","author":"Buda-Okreglak","year":"2004","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.revmed.2004.12.013_bib124","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.revmed.2004.12.013_bib125","doi-asserted-by":"crossref","DOI":"10.1002\/art.20146","article-title":"Absence of efficacy of infliximab in the trial of Remicade in primary Sj\u00f6gren\u2019s syndrome (TRIPSS): randomized controlled trial","author":"Mariette","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2004.12.013_bib126","first-page":"3982S","article-title":"Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties","volume":"9","author":"Carnahan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.revmed.2004.12.013_bib127","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1182\/blood-2002-07-1952","article-title":"Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies","volume":"101","author":"Faderl","year":"2003","journal-title":"Blood"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:13:55Z","timestamp":1759335235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0248866305000160"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2004.12.013","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Le rituximab : une bioth\u00e9rapie originale dans les maladies auto-immunes","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2004.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}